CJC-1295 + Ipamorelin Stack Dosing & Protocols — Research Reference

The CJC-1295 + Ipamorelin combination is the most-cited GHRH + GHRP research stack. CJC-1295 (GHRH analog) amplifies the amplitude of GH pulses while Ipamorelin (selective GHRP) triggers additional GH release without the cortisol or prolactin signal seen with older GHRPs. This guide compiles standard combined-administration references.

Reconstitution for Research

Both peptides are typically supplied lyophilized. Reconstitute each separately with bacteriostatic water (2 mg/2 mL is standard) or use a pre-blended research vial. Refrigerated stability typically extends 30+ days per COA.

Reference Dose Ranges in Published Research

| Research model tier | Typical range | Notes | |---|---|---| | Standard research dose | 100 mcg CJC-1295 + 100 mcg Ipamorelin per administration | Most-cited entry stack | | Higher tier | 200 mcg + 200 mcg per administration | Larger pulse-amplitude research; saturation begins above this | | Multi-dose daily | 100/100 mcg × 2–3 daily administrations | Mimics endogenous pulsatile pattern |

Scheduling

Subcutaneous administration timed to natural GH-pulse windows: 30–60 min before sleep (largest endogenous pulse) and optionally 30 min pre/post-fasted exercise. Avoid administration within 90 minutes of a meal — postprandial somatostatin tone suppresses the GH response.

Cycling in the Published Literature

Most-cited research cycle is 8–12 weeks on / 4 weeks off, primarily to assess pituitary responsiveness over time. Continuous longer-duration research has been published without pituitary downregulation when pulsatility is preserved.

Common Research Endpoint Markers

IGF-1, IGFBP-3 (cumulative GH-axis output), random and stimulated GH pulse amplitude (research labs only), body-composition (DEXA), sleep-stage architecture. Cortisol and prolactin should remain unchanged if Ipamorelin is appropriately selective.

Common Research Pairings

Stand-alone GHRH + GHRP is itself a complete research stack. Some research pairs it with [tesamorelin](/research/hubs/tesamorelin) for visceral-adipose endpoints, though this is mechanistically redundant. Pairing with MK-677 is less common due to differing pharmacokinetic profile and prolonged elevation.

Storage & Stability

Lyophilized at 2–8 °C protected from light. Reconstituted solutions refrigerated; minimize freeze-thaw.

Frequently Asked Questions

Why combine GHRH and GHRP?

GHRH and GHRPs activate distinct pituitary pathways. Co-administration produces a synergistic GH release greater than either alone, while preserving the pulsatile pattern that downregulation studies suggest matters for receptor health.

Should CJC-1295 with or without DAC be used?

No-DAC CJC-1295 (Mod GRF 1-29) is preferred for pulsatile-pattern research because its short half-life allows natural between-pulse troughs. CJC-1295-DAC produces sustained elevation, useful for different research questions but breaks the pulsatile model.

Research-Use Disclosure

All content is provided strictly for laboratory research purposes. Compounds discussed are research chemicals and are not for human or veterinary consumption. Dosing ranges referenced below are summaries of published preclinical and clinical research literature compiled for laboratory reference only — they are not medical recommendations.